MON-172 - Psychiatric Outcomes in Adolescents with Polycystic Ovary Syndrome Receiving Oral Contraceptives, Metformin, and/or Spironolactone: A Retrospective Cohort Analysis

Study

Objective:
To evaluate the effects of polycystic ovary syndrome (PCOS) therapies in female adolescents on anxiety and depression outcomes and assess associations between baseline hormonal and metabolic characteristics and psychological outcomes.

Methods:
Retrospective cohort study at a tertiary care center included 50 adolescents aged 12–21 years with PCOS who received oral contraceptive pills (OCPs), metformin, spironolactone, or combination therapy for at least 5 months. Participants had anxiety, depression, or both and were receiving psychological treatment. They were categorized into OCP monotherapy, metformin/spironolactone, or combination therapy. Changes in symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7). Associations with clinical, anthropometric, and biochemical parameters were evaluated.

Results:
Anxiety and depression were present in 92% and 84%, respectively. Combination therapy was associated with a significant reduction in GAD-7 scores (median –3.0; IQR –6.5 to –1.43; p = 0.0485), whereas no significant changes in GAD-7 or PHQ-9 scores were observed in other treatment groups. Higher baseline free testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEA-S) were associated with worsening GAD-7 scores (p = 0.043, 0.038, and 0.017, respectively).

Conclusions:
Combination therapy was associated with improved anxiety, suggesting a synergistic benefit of hormonal and metabolic interventions. Positive correlations between baseline androgen levels and anxiety severity highlight a potential role of androgen excess in heightened anxiety. Routine psychological screening in adolescent PCOS care is crucial to optimize mental and reproductive health outcomes.
Keywords:
Adolescent PCOS; Anxiety; Depression; Free testosterone; Oral contraceptives; Metformin; Spironolactone; Mental health.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*